Insider Selling: Agios Pharmaceuticals, Inc. (AGIO) Insider Sells 2,146 Shares of Stock
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Scott Biller sold 2,146 shares of the business’s stock in a transaction on Friday, July 7th. The shares were sold at an average price of $55.00, for a total value of $118,030.00. Following the completion of the sale, the insider now owns 8,410 shares of the company’s stock, valued at $462,550. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Scott Biller also recently made the following trade(s):
- On Wednesday, June 21st, Scott Biller sold 4,292 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $55.00, for a total value of $236,060.00.
Shares of Agios Pharmaceuticals, Inc. (AGIO) traded up 3.36% during trading on Tuesday, reaching $56.33. The company’s stock had a trading volume of 515,226 shares. The stock’s 50-day moving average is $51.10 and its 200-day moving average is $49.19. Agios Pharmaceuticals, Inc. has a 12-month low of $35.84 and a 12-month high of $67.74. The stock’s market cap is $2.72 billion.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($1.56) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.80) by $0.24. The firm had revenue of $10.51 million for the quarter, compared to the consensus estimate of $9.65 million. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. The company’s quarterly revenue was down 66.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.64) earnings per share. Equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post ($6.44) earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. C WorldWide Group Holding A S purchased a new position in Agios Pharmaceuticals during the first quarter worth $105,000. Bank of Montreal Can boosted its stake in shares of Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 216 shares in the last quarter. Blue Sky Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the first quarter worth approximately $129,000. Russell Investments Group Ltd. boosted its stake in shares of Agios Pharmaceuticals by 163.9% in the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 1,583 shares in the last quarter. Finally, Advantage Investment Management LLC boosted its stake in shares of Agios Pharmaceuticals by 109.7% in the first quarter. Advantage Investment Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock worth $190,000 after buying an additional 1,700 shares in the last quarter. Institutional investors own 83.66% of the company’s stock.
Several analysts recently issued reports on AGIO shares. Oppenheimer Holdings, Inc. set a $75.00 price target on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, June 11th. Cann restated a “buy” rating and issued a $75.00 price target on shares of Agios Pharmaceuticals in a research note on Sunday, June 11th. Canaccord Genuity set a $90.00 price target on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, May 18th. Zacks Investment Research upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, April 28th. Finally, ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $62.88.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.